Catalog No.
PHK44901
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human ITCH (Met1-Gly141).
Applications
ELISA, IHC, WB
Recommended Dilution
| Application |
Dilution |
| ELISA |
1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000 |
Target
Atrophin-1-interacting protein 4, HECT-type E3 ubiquitin transferase Itchy homolog, NFE2-associated polypeptide 1, NAPP1, E3 ubiquitin-protein ligase Itchy homolog, ITCH, Itch, AIP4
Purification
Purified by antigen affinity column.
Accession
Q96J02
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Note
For research use only.
Comparative Analysis of Sociodemographic, Clinical Features, Laboratory Findings, and Treatment Protocols in Generalized and Localized Cutaneous Lichen Planus., PMID:40104468
Safety and Efficacy of Radiotherapy Combined With Sintilimab in Advanced NSCLC Patients Who Progressed on First or Second Line Therapy: A Prospective, Multiple Center, and Single-Arm Study., PMID:40116232
Taraxasterol attenuates inflammatory responses in a 2,4-dinitrochlorobenzene-induced atopic dermatitis mouse model via inactivation of the MAPK and NF-κB pathways., PMID:40119084
A case of pembrolizumab-induced bullous pemphigoid treated with dupilumab., PMID:40125009
Mercury poisoning-associated membranous nephropathy and autoimmune encephalitis., PMID:40128702
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes., PMID:40142885
Diagnostic challenges in DAT-negative autoimmune haemolytic anaemia., PMID:40154553
Safety and pharmacokinetics of long-acting plasma kallikrein inhibitor navenibart (STAR-0215) in healthy adults., PMID:40158724
Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis., PMID:40158906
A case of remarkable response to combined radiation therapy, enfortumab vedotin, and pembrolizumab in metastatic urothelial carcinoma., PMID:40160871
Assessing the Clinical Efficacy of Dupilumab and Its Impact on the Quality of Life of Adult Atopic Dermatitis Patients: A Systematic Review., PMID:40161158
Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice., PMID:40165566
Phase 1, First-In-Human, Single-/Multiple-Ascending Dose Study of Iluzanebart in Healthy Volunteers., PMID:40166927
Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: A Systematic Review and Meta-analysis of Randomized Controlled Trials., PMID:40186041
Efficacy and Safety of Dupilumab in the Treatment of Refractory Atopic Dermatitis in Older Adults: A Retrospective, Single-Center Study., PMID:40186050
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial., PMID:40199609
Effectiveness and Safety of Nemolizumab in Patients with Prurigo Nodularis: a Systematic Review and Meta-Analysis of Randomized Controlled Trials., PMID:40205064
[Chronic Pruritus: A Review of Its Pathophysiology and Current Treatments]., PMID:40214004
[Observation of the efficacy of dupilumab for treatment of atopic dermatitis in the elderly]., PMID:40219560
Dual roles of CXCR4 (C-X-C motif chemokine receptor 4) in promoting entry of ebolavirus and targeting excessive glycoprotein for reticulophagic degradation to facilitate viral fitness., PMID:40223186
Case Report: Subacute cutaneous lupus erythematosus induced by the anti-PD-1 antibody camrelizumab combined with chemotherapy., PMID:40226630
Long-Term Efficacy and Potential Predictors of Tralokinumab Dose Optimization in Elderly Patients: A Multicentre Study., PMID:40232593
Topical Application of Fluoxetine Improves DNCB-Induced Atopic Dermatitis in Mice., PMID:40243303
Sarcoptic mange in cattle: Effects of treatment with eprinomectin topical solution on performance, behavior changes, and adrenal and systemic responses to ACTH challenge., PMID:40252507
Neuronal Mechanisms of Psoriatic Itch: Role of IL-17R/ERK/TRPV4 Signaling Pathway., PMID:40252992
Complete Resolution of Atypical Paraneoplastic Pemphigus Following Treatment With Dupilumab., PMID:40264631
New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review., PMID:40282922
Possible Clinical Effects of Ketoconazole on Sorafenib-induced Hand-Foot Skin Reaction and Cytoprotection Mechanisms of Antifungal Agents against Multikinase Inhibitor-induced Keratinocyte Toxicity., PMID:40289816
Molecular Hydrogen Capsule Therapy for Primary Biliary Cholangitis With Elevated IgG4: A Case Report on Immune Marker Normalization., PMID:40295001
Assessing the clinical progress of the bispecific nanobody sonelokimab., PMID:40297934
Secukinumab as a Novel Treatment for Chronic Netherton Syndrome in a Young Adult., PMID:40299794
Decentralization of snakebite antivenom treatment to indigenous community health centers in the Brazilian Amazon: From demand to the first treatment (the SAVING Program)., PMID:40305592
Alpha-gal syndrome: Recognizing and managing a tick-bite-related meat allergy., PMID:40312115
Efficacy and Safety of Rilzabrutinib in Patients With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Proof-of-Concept Phase II Clinical Trial., PMID:40317187
Cutaneous Adverse Events Following Nemolizumab Administration: A Review., PMID:40364058
Nemolizumab Improves Pruritus in Patients With Intrinsic Atopic Dermatitis Lacking Atopic Predisposition: A Single-Centre Pilot Retrospective Cohort Study., PMID:40372094
Angioedema without urticaria: Diagnosis and management., PMID:40380367
Expanding the potential of monoclonal antibodies against interleukin-4 and interleukin-13 in genodermatoses: A case series on the efficacy and safety of dupilumab in epidermolysis bullosa and ichthyosis., PMID:40386013
Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis., PMID:40403168
Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: a randomized clinical trial., PMID:40413023
A phase I, randomized, placebo-controlled, double-blind, ascending-dose and single-center study to evaluate immunogenicity and safety of a live attenuated tetravalent dengue vaccine (KD-382) in Flavivirus antibody-naïve healthy adults., PMID:40435636
Efficacy and safety of Omalizumab in the treatment of CSU: a meta-analysis of a randomized controlled trial., PMID:40439896
First successful treatment of epidermolytic Ichthyosis with Vunakizumab: A Case Report., PMID:40453098
Evaluating remibrutinib in the treatment of chronic spontaneous urticaria., PMID:40455080
Cutaneous adverse effects of combination epidermal growth factor receptor inhibitor and immune checkpoint inhibitor cancer therapy., PMID:40455297
Management of local and delayed cutaneous hypersensitivity reactions to anti-CGRP antibodies: implications for continuing treatment., PMID:40456979
Polynucleotides Enhance Skin Barrier Function and Reduce Inflammation in a 2,4-Dinitrochlorobenzene-Induced Mouse Model of Atopic Dermatitis., PMID:40484710
Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system., PMID:40491908
For research use only. Not for human or drug use.
